
Bristol-Myers Squibb Company BMY
$ 59.46
-0.15%
Annual report 2025
added 02-11-2026
Bristol-Myers Squibb Company DSO Ratio 2011-2026 | BMY
Annual DSO Ratio Bristol-Myers Squibb Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 83.9 | 81.9 | 84.4 | 76.1 | 70.3 | 69.5 | 107 | 96.5 | 111 | 104 | 94.8 | 77.9 | 74.8 | 63.9 | 64.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 111 | 63.9 | 84 |
Quarterly DSO Ratio Bristol-Myers Squibb Company
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.6 | 88.9 | 86.1 | 81.8 | 79.8 | 84.9 | 82 | 80.2 | - | 39.1 | 32.7 | 70 | - | 71.7 | 68.9 | 70.7 | 70.1 | 73.6 | 76.6 | 68.5 | 88.3 | 117 | 112 | 104 | 89.5 | 95.6 | 95.4 | 108 | 106 | 109 | 112 | 110 | 96.5 | 103 | 104 | 102 | 91.5 | 96.4 | 94.2 | 86.8 | 72.7 | 78.9 | 79.5 | 80.8 | 69 | 75.4 | 75.7 | 76.7 | 67.1 | 75.3 | 63.3 | 59.3 | 62.6 | 63.9 | 62.9 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 117 | 32.7 | 82.8 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M | ||
|
Happiness Biotech Group Limited
HAPP
|
29 | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
271 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
39.1 | $ 32.59 | -6.89 % | $ 877 M | ||
|
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M | ||
|
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | ||
|
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | ||
|
IMV
IMV
|
2.16 K | - | - | $ 13.1 M | ||
|
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.7 | 3.03 % | $ 452 M | ||
|
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
198 | $ 0.86 | -1.42 % | $ 143 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | ||
|
Compugen Ltd.
CGEN
|
400 | $ 2.8 | 7.28 % | $ 262 M | ||
|
Anika Therapeutics
ANIK
|
76.5 | $ 14.88 | -0.93 % | $ 213 M | ||
|
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | ||
|
Incyte Corporation
INCY
|
66.6 | $ 97.16 | -0.26 % | $ 19 B | ||
|
Ionis Pharmaceuticals
IONS
|
20.5 | $ 75.56 | -0.29 % | $ 12.1 B | ||
|
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.4 | -1.16 % | $ 5.6 M | ||
|
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | ||
|
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
559 | $ 1.61 | 2.55 % | $ 189 M | ||
|
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M |